Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma

被引：4

作者：

Ophuis, C. M. C. Oude ^{[1
]}

van Akkooi, A. C. J. ^{[2
]}

Rutkowski, P. ^{[4
]}

Powell, W. E. M. ^{[5
]}

Robert, C. ^{[6
]}

Testori, A. ^{[8
]}

van Leeuwen, B. L. ^{[3
]}

Siegel, P. ^{[9
]}

Eggermont, A. M. M. ^{[7
]}

Verhoef, C. ^{[1
]}

Grunhagen, D. J. ^{[1
]}

机构：

[1] Erasmus MC Canc Inst, Dept Surg Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands

[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Surg, Amsterdam, Netherlands

[3] Univ Groningen, Univ Med Ctr Groningen, Dept Surg Oncol, Groningen, Netherlands

[4] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland

[5] St Georges Fdn Univ Hosp, Melanoma Unit, London, England

[6] Canc Inst Gustave Roussy, Dept Dermatol & Allergol, Villejuif, France

[7] Canc Inst Gustave Roussy, Board Directors, Villejuif, France

[8] European Inst Oncol, Div Dermatooncol Surg, Milan, Italy

[9] Charite, Dept Dermatol & Allergol, Berlin, Germany

来源：

BRITISH JOURNAL OF SURGERY | 2017年 / 104卷 / 06期

关键词：

DISSECTION; PROGNOSIS; SURVIVAL; TIME; MULTICENTER; RECURRENCE; UPDATE;

D O I：

10.1002/bjs.10475

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

BackgroundNodal staging with sentinel node biopsy (SNB) and completion lymph node dissection (CLND) provides prognostic information to patients with melanoma and their physicians. It is not known whether the timing of CLND is associated with survival outcome and/or CLND tumour load. This study investigated whether CLND timing is associated with CLND tumour load, disease-free survival (DFS) and/or melanoma-specific survival (MSS). MethodsA retrospective cohort of patients with SNB-positive melanoma from nine European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group centres undergoing surgery between 1993 and 2009 were examined. Patients were selected based on availability of CLND and follow-up data. The CLND interval was defined as the number of days between diagnosis and CLND. Patient and tumour characteristics were collected. Five-year DFS and MSS rates were calculated. Cox and logistic regression analysis were performed, adjusting for known prognostic/predictive indicators. ResultsA total of 784 patients were included in the study. Their median age was 51 (i.q.r. 40-62) years, and 418 patients (533 per cent) were men. Median Breslow thickness was 30 (i.q.r. 20-50)mm, and 148 patients (189 per cent) had a residual tumour load. Median CLND interval was 84 (i.q.r. 65-105) days. Five-year DFS and MSS rates were not significantly different for patients operated on with a median CLND interval of less than 84days and those with an interval of at least 84days (DFS: 542 versus 533 per cent respectively; MSS: 669 versus 651 per cent). In a multivariable Cox model, CLND interval was not a significant prognostic indicator. CLND interval was negatively correlated with identification of positive non-sentinel nodes, but following adjustment for known risk factors this effect was no longer found. ConclusionThe time interval between diagnosis of melanoma and CLND did not influence CLND tumour load, DFS or MSS. No rush

引用

页码：726 / 733

页数：8

共 50 条

[31] Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients
Kesmodel, Susan B.
Kronenfeld, Joshua P.
Zhao, Wei
Koru-Sengul, Tulay
Goel, Neha
Weingrad, Daniel N.
Hernandez-Aya, Leonel
Lutzky, Jose
Feun, Lynn
Garland-Kledzik, Mary
Crystal, Jessica S.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (12) : 7671 - 7685
[32] The place of sentinel node biopsy in melanoma after the Multicenter Selective Lymphadenectomy Trial
Thomas, JM
[J]. ANZ JOURNAL OF SURGERY, 2006, 76 (03) : 98 - 99
[33] Necessity of Completion Pelvic Lymph Node Dissection after Positive Inguinal Sentinel Lymph Node Biopsy in Cutaneous Melanoma
Carpenter, K.
Forster, M. R.
Sarantou, T.
Salo, J. C.
Hill, J. S.
White, R. L., Jr.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S111 - S111
[34] Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma
de Vries, M.
Vonkeman, W. G.
van Ginkel, R. J.
Hoekstra, H. J.
[J]. EJSO, 2006, 32 (07): : 785 - 789
[35] Recurrence Patterns and Clinical Management after a Positive Sentinel Node Biopsy in Melanoma Patients
de Menezes, Jacqueline N.
Arra, Dante A. S. M.
Lobo, Matheus M.
Pinto, Clovis A. L.
Lima, Joao P. S. N.
Silva, Milton J. B.
Duprat Neto, Joao P.
Bertolli, Eduardo
[J]. CANCER INVESTIGATION, 2023, 41 (10) : 830 - 836
[36] Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma
Sabran J. Masoud
Jennifer A. Perone
Norma E. Farrow
Paul J. Mosca
Douglas S. Tyler
Georgia M. Beasley
[J]. Current Treatment Options in Oncology, 2018, 19
[37] Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma
Masoud, Sabran J.
Perone, Jennifer A.
Farrow, Norma E.
Mosca, Paul J.
Tyler, Douglas S.
Beasley, Georgia M.
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (11)
[38] Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection in Melanoma
Ross, Merrick I.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (06) : 368 - 371
[39] Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: a critical review
Eiger, Daniel
de Oliveira, Daniel Arcuschin
de Oliveira, Renato Leao
Sousa, Murilo Costa
Cavalcante Brandao, Mireille Darc
de Oliveira Filho, Renato Santos
[J]. ANAIS BRASILEIROS DE DERMATOLOGIA, 2018, 93 (04) : 553 - 558
[40] Completion lymphadenectomy following positive sentinel node biopsy may not be justified in early stage breast cancer
B. D. Barry
N. J. Aherne
M. A. Kelly
N. Relihan
H. P. Redmond
[J]. Irish Journal of Medical Science, 2002, 171 (Suppl 2)

← 1 2 3 4 5 →